Bioline Of Israel Says Licensing Deal With Cypress Big Quarterly Win
This article was originally published in PharmAsia News
Executive Summary
Israel's BiolineRX says its agreement to license one of its drugs to Cypress Bioscience to develop has given it not only a third-quarter profit, but a four-fold increase in revenue